August 3rd 2025
Nurses should be familiar with PET scan protocol and what to ask patients with lung and bone cancers before administering biology-guided radiation therapy.
Biomarkers Predict Osteosarcoma Treatment Response
February 2nd 2020The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.
FDA Approves Tazemetostat for Epithelioid Sarcoma
January 24th 2020The FDA has granted an accelerated approval to tazemetostat (Tazverik) for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.
Trabectedin Now FDA-Approved for Metastatic Soft Tissue Sarcomas
October 23rd 2015Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue sarcomas-liposarcoma and leiomyosarcoma-who previously received chemotherapy that included an anthracycline.